
MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Últimos 235 días · 12/11/25 — 29/10/26
+78.58%
Precio
$ 49.660
Var. %
+3,07%
Volumen operado
5.049
Precio MRK
US$ 149,54
Teórico (precio / ratio)
MRK ÷ 5
US$ 29,91
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,3 %
Frecuencia (estimada)
Trim.
Próxima ex-date
sin fecha
Próximo pago
sin fecha
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 5
USD 0,68
Sí, existe el CEDEAR de MRK (Merck & Co. Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es MRK.
El ticker del CEDEAR de Merck & Co. Inc. en Argentina es MRK. La acción subyacente cotiza en NYSE con el símbolo MRK.
El CEDEAR MRK tiene un ratio de 5:1. Eso significa que 5 CEDEARs equivalen a 1 acción de MRK.
El CEDEAR MRK cotiza hoy a $ 49.660 en pesos argentinos, con una variación diaria de +3,07%.
Otros CEDEARs de Salud.


Yahoo · 29 de oct de 2026
Moby summary of Merck & Co., Inc.'s Q3 2026 earnings call

Yahoo · 29 de oct de 2026
Merck (NYSE:MRK) reported new Phase 3 data at ESMO 2026 showing KEYTRUDA monotherapy benefits in advanced endometrial cancer. Sacituzumab tirumotecan delivered…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 31,72
vs teórico
+6,06%
Cotización MEP implícita
$ 1.565,57
Cotización
US$ 29,71
vs teórico
-0,66%
Cotización Cable implícita
$ 1.671,49
La acción subyacente MRK (Merck & Co. Inc.) cotiza a US$ 149,54 en su mercado de origen (NYSE).
El precio teórico del CEDEAR MRK se calcula dividiendo el precio de MRK por el ratio (5). Hoy resulta en US$ 29,91.
En BYMA podés operar MRK en pesos, MRKD en dólar MEP y MRKC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR MRK en pesos argentinos, con datos de data912.

Yahoo · 29 de oct de 2026
A steep 12.6% sell-off in Alphabet (GOOGL) dragged down the broader market, pulling semiconductor and software names like Micron (MU), Intel (INTC), and Marvell…

ChartMill · 29 de oct de 2026
Dow Jones components on Oct. 29, 2026: Merck, Nike and Home Depot led gainers, while Alphabet and Caterpillar had the largest declines. Merck rose 3.92%.

Yahoo · 29 de oct de 2026
Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.

Yahoo · 29 de oct de 2026
Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum.

Yahoo · 29 de oct de 2026
Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio.
Noticias vía Finnhub